TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs

TG Therapeutics Provides Regulatory Update

November 30, 2021 7:30 AM EST

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and UKONIQ® (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Michael S. Weiss, Chairman and Chief Executive Officer... More